Thymosin α1: A historical overview

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

Thymosin α 1 (Tα1), initially isolated from thymus, was characterized by Allan Goldstein in 1977. Since the beginning, our studies were aimed at evaluating its immunomodulating effects when used in combination with cytokines and chemotherapy. Combination therapies have now proved to be effective in inhibiting tumoral growth and in controlling infective diseases especially in the immunocompromised host. More recent studies showed that Tα1 molecule increased major histocompatibility complex (MHC) class-1 and Toll-like receptor expression as well as cytokine production, suggesting its immunoregulatory role. Overall these results led us to start pilot clinical trials on patients with hepatitis C and cancer.

Original languageEnglish
Title of host publicationAnnals of the New York Academy of Sciences
Pages14-20
Number of pages7
Volume1112
DOIs
Publication statusPublished - Sep 2007

Publication series

NameAnnals of the New York Academy of Sciences
Volume1112
ISSN (Print)00778923
ISSN (Electronic)17496632

Keywords

  • Combination therapies
  • Thymosin α1

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Thymosin α1: A historical overview'. Together they form a unique fingerprint.

Cite this